Ok then .... if ASCO is so exclusive and / or prestigious let us know all the other drugs featured at the 2023 ASCO conference (link provided below) that have commanded huge big pharma license deals in the last 12 months (since) as a result of their presentations - you know for the likes of $100 million plus as @antibotter often tells us each of our DEP® drugs are worth ( E.g. Post #:65156161 ) .... I am not sure ASCO has the clout you believe it does ?
https://meetings.asco.org/meetings/2023-asco-annual-meeting/299/program-guide/scheduled-sessions
..... and let's not forget we have been here many times before ....everyone claimed being featured at ESMO in 2022 was prestigious and look how that has turned out ?
https://www.starpharma.com/news/sto...bazitaxel-in-prostate-cancer-asx-announcement
- Starpharma presented promising anti-tumour activity data in prostate cancer at the European Society of Medical Oncology (ESMO) Congress on Sunday
..... and of course most on here also claimed that the International Conference on Molecular Targets and Cancer Therapeutics held in Boston in 2023 was going to create 'interest' in our DEP® drugs because it was such a recognised Cancer conference ....
https://www.miragenews.com/starpharma-presents-dep-irinotecan-combo-data-1093628/
Starpharma Presents DEP Irinotecan Combo Data
The data will be presented in Boston at the International Conference on Molecular Targets and Cancer Therapeutics, co-hosted by the American Association of Cancer Research, the National Cancer Institute and the European Organisation for Research and Treatment of Cancer.
.... and then of course there was the Starpharma presentation at the 'specialised' Targeted Radiopharmaceuticals Summit in Europe in December 2023 in Berlin ... that was also supposedly going to 'put us on the map' ?
.... and now the savior in 2024 is supposedly going to be ASCO ??? I could go on and on and on given the number of supposed renowned conferences Starpharma have presented at over the years that have been unsuccessful in producing any DEP® License deal at all to date.... IMHO it is time to accept what the new CEO told us recently in the webinar ..... big pharma are just not interested in our DEP® trialed drugs; hence why they haven't signed a DEP® license deal.
This leaves us to seek interest from a second tier type pharma group prepared to undertake another trial at their expense and I cannot see that commanding the types of upfront dollars that have been suggested on the SPL forums over the years .... simples
